Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19

Clin Infect Dis. 2024 Feb 27:ciae105. doi: 10.1093/cid/ciae105. Online ahead of print.


Among U.S. adults at risk for severe COVID-19 in Epic Cosmos, the lowest rate of hospitalization was among those receiving three or more mRNA vaccine doses and nirmatrelvir-ritonavir (aHR 0.22, 95%CI: 0.19-0.24). Adults who are at high-risk of severe COVID-19 disease, including vaccinated persons, should be considered for antiviral treatment.

Keywords: SARS-CoV-2; covid-19; nirmatrelvir-ritonavir; vaccination.